Search Results - (Author, Cooperation:M. Lauer)

Showing 1 - 8 results of 8, query time: 0.14s Refine Results
  1. 1
    M. Lauer ; H. Valantine ; F. S. Collins
    Nature Publishing Group (NPG)
    Published 2016
    Staff View
    Publication Date:
    2016-03-05
    Publisher:
    Nature Publishing Group (NPG)
    Print ISSN:
    0028-0836
    Electronic ISSN:
    1476-4687
    Topics:
    Biology
    Chemistry and Pharmacology
    Medicine
    Natural Sciences in General
    Physics
    Keywords:
    Congresses as Topic ; *National Institutes of Health (U.S.)/economics/organization & administration ; *Organizational Policy ; Sexual Harassment/*prevention & control/statistics & numerical data ; United States ; Workplace
    Published by:
    http://www.nature.com/

    Latest Papers from Table of Contents or Articles in Press
  2. 2
    M. A. Paley ; D. C. Kroy ; P. M. Odorizzi ; J. B. Johnnidis ; D. V. Dolfi ; B. E. Barnett ; E. K. Bikoff ; E. J. Robertson ; G. M. Lauer ; S. L. Reiner ; E. J. Wherry
    American Association for the Advancement of Science (AAAS)
    Published 2012
    Staff View
    Publication Date:
    2012-12-01
    Publisher:
    American Association for the Advancement of Science (AAAS)
    Print ISSN:
    0036-8075
    Electronic ISSN:
    1095-9203
    Topics:
    Biology
    Chemistry and Pharmacology
    Computer Science
    Medicine
    Natural Sciences in General
    Physics
    Keywords:
    Animals ; CD8-Positive T-Lymphocytes/*immunology ; Hepatitis B, Chronic/*immunology ; Humans ; Liver/virology ; Lymphocyte Activation ; Mice ; Mice, Knockout ; Stem Cells/immunology ; T-Box Domain Proteins/genetics/*metabolism ; T-Lymphocyte Subsets/*immunology
    Published by:
    http://www.aaas.org/

    Latest Papers from Table of Contents or Articles in Press
  3. 3
    Lauer, M. ; Wulff, G.

    Amsterdam : Elsevier
    Staff View
    ISSN:
    0022-328X
    Source:
    Elsevier Journal Backfiles on ScienceDirect 1907 - 2002
    Topics:
    Chemistry and Pharmacology
    Type of Medium:
    Electronic Resource
    URL:
    http://linkinghub.elsevier.com/retrieve/pii/S0022-328X(00)99290-8

    Articles: DFG German National Licenses
  4. 4
    Lauer, M. ; Samuel, O. ; Kagan, H.B.

    Amsterdam : Elsevier
    Staff View
    ISSN:
    0022-328X
    Source:
    Elsevier Journal Backfiles on ScienceDirect 1907 - 2002
    Topics:
    Chemistry and Pharmacology
    Type of Medium:
    Electronic Resource
    URL:
    http://dx.doi.org/10.1016/S0022-328X(00)92357-X

    Articles: DFG German National Licenses
  5. 5
    Staff View
    ISSN:
    1435-1463
    Source:
    Springer Online Journal Archives 1860-2000
    Topics:
    Medicine
    Type of Medium:
    Electronic Resource
    URL:
    http://dx.doi.org/10.1007/BF01273325

    Articles: DFG German National Licenses
  6. 6
    Lauer, M. ; Samuel, O. ; Kagan, H.B.

    Amsterdam : Elsevier
    Staff View
    ISSN:
    0022-328X
    Source:
    Elsevier Journal Backfiles on ScienceDirect 1907 - 2002
    Topics:
    Chemistry and Pharmacology
    Type of Medium:
    Electronic Resource
    URL:
    http://linkinghub.elsevier.com/retrieve/pii/S0022-328X(00)92357-X

    Articles: DFG German National Licenses
  7. 7
    Kalus, P. ; Senitz, D. ; Lauer, M. ; Beckmann, H.
    Springer
    Published 1999
    Staff View
    ISSN:
    1435-1463
    Keywords:
    Keywords: Interneurons ; chandelier neurons ; axon cartridges ; synapses ; immunocytochemistry ; parvalbumin ; anterior cingulate cortex ; schizophrenia.
    Source:
    Springer Online Journal Archives 1860-2000
    Topics:
    Medicine
    Notes:
    Summary. Axon cartridges are the specific terminal structures of GABAergic inhibitory chandelier interneurons. Cartridges form axo-axonal synapses with local projection neurons, thus modulating the neuronal output of diverse brain areas. In order to examine the distribution of cartridges, the anterior cingulate cortices from the brains of schizophrenic patients and control persons were examined with an antibody against parvalbumin. Axon cartridges were mainly located in layers V and VI. In our study, schizophrenic patients showed a significantly higher density of axon cartridges than controls. These findings add new evidence for disturbances of the circuitry of the anterior cingulate cortex in schizophrenia implicating that there may be an elevated inhibitory influence on the cortical output of this brain region.
    Type of Medium:
    Electronic Resource
    URL:
    http://dx.doi.org/10.1007/s007020050197

    Articles: DFG German National Licenses
  8. 8
    Staff View
    ISSN:
    1435-1420
    Keywords:
    Key words Intravenous immunglobulin therapy ; Guillain-Barré-syndrome ; plasma exchange (PE) ; expenses ; Schlüsselwörter Intravenöse Immunglobulintherapie ; akutes Guillain-Barré-Syndrom (GBS) ; Komplikationen ; Plasmaseparationstherapie ; Kosten
    Source:
    Springer Online Journal Archives 1860-2000
    Topics:
    Medicine
    Description / Table of Contents:
    Zusammenfassung In der aktuellen Diskussion um das adäquate Therapieverfahren (intravenöse Immunglobulintherapie vs. Plasmaseparation) beim akuten Guillain-Barré-Syndrom (GBS) besteht derzeit kein allgemeingültiger Konsens. Die vorliegende Untersuchung über Komplikationshäufigkeit resp.-schwere von 155 Plasmaseparationen und die Kostenevaluierung beider Verfahren leistet hierzu einen Beitrag. In 27% aller Plasmaaustauschtherapien wurden Ereignisse wie allergische Symptome (5%), Atemnot (3,9%), Unruhe (3,9%) Rhythmusstörungen (3,2%), Wadenkrämpfe (2,6%) u.a. beobachtet. 12,5% aller Ereignisse lassen sich auf das Plasmaseparationsverfahren (PS) zurückführen, aber keines dieser stellte eine ernsthafte Gefahr für die Patienten dar. Es zeigen sich signifikante Laborveränderungen unmittelbar im Anschluß an die PS (Gesamtkalzium, Antithrombin III, Thrombozyten (p=0,003), die jedoch klinisch bedeutungslos sind. Die Kosten beider Verfahren belaufen sich auf etwa 6500 bis 7000 DM, exklusive Arbeitszeit (Stand: April 1997). Eine Therapie mit intravenösen Immunglobulinen ist technisch weniger aufwendig als eine Plasmaseparation (PS). Die Kosten belaufen sich in etwa gleich. In dieser Untersuchung traten bei der PS keine ernsthaften Nebenwirkungen auf.
    Notes:
    Summary There is no consensus about the most effective therapy in the treatment of Guillain-Barré-syndrome: plasma exchange (PE) versus intravenous immunglobulin therapy. The present investigation examines the side effects of 155 plasma exchanges. Furthermore, the analysis of all expenses for both treatments will contribute to the discussion of the preferable treatment. There are side effects in 27% of all plasma exchanges (PE): allergic symptoms (5%), dyspnoea (3.9%), restlessness (3.9%), arrhythmias (3.2%), muscle cramps (2.6%), etc. Those side effects caused by PE (12.5%) did not really endanger patients. There are significant changes in laboratory values after PE (calcium, antithrombin III, thrombocyte counts; p=0.003), but without clinical significance. The expenses for both therapies are estimated between 6,500 and 7,000 DM (April 1997). The intravenous immunglobulin therapy is easier to perform.
    Type of Medium:
    Electronic Resource
    URL:
    http://dx.doi.org/10.1007/s003900050196

    Articles: DFG German National Licenses